Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thalassemia major patients with serum ferritin concentration between 800 to 3,000 ng/ml and were over 13 years of age~Exclusion Criteria:~* Known intolerance to one of the trial treatments~* Platelet count \< 100,000/mm3 or or leukocyte count \< 3,000/mm3~* Severe liver damage indicated by ascites~* Heart failure

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
- 2 (Type: ACTIVE_COMPARATOR): Deferiprone alone at 75 mg/kg divided into three oral daily doses

Based on this trial design, predict the completion outcome and termination type (if applicable).